Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GLUT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GLUT1 Extracellular Loop Peptides / Recombinant Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View GLUT1 Products |
| Gene Delivery | GLUT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformation preserved. |
View GLUT1 Products |
| Benchmark Ab | Anti-GLUT1 Recombinant Antibody Recombinant positive control for flow cytometry and IHC. |
View GLUT1 Products |
| Validator | GLUT1 siRNA Set For knockdown verification in functional assays. |
View GLUT1 Products |
| Related Target A | GLUT3 (SLC2A3) High-homology brain glucose transporter; critical for off-target selectivity screening. |
View GLUT3 Products |
| Related Target B | GLUT4 (SLC2A4) Insulin-regulated glucose transporter; counter-screening essential to prevent systemic metabolic toxicity. |
View GLUT4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native 12-TM Conformation Preservation | Lentivirus-based expression system for stable host cell line generation (HEK293/CHO) |
| Subfamily Selectivity (GLUT3/4 Counter-screening) | Sequence-verified ORF lentiviral panels for parallel cell-line construction |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live GLUT1/SLC2A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GLUT1 therapeutics is intensifying, with major players shifting focus from traditional non-selective small molecules to isoform-selective inhibitors and antibody-drug conjugates (ADCs) targeting the Warburg effect. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific extracellular loops and combination regimens with immunotherapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Bayer, Kadmon Pharmaceuticals | Solid Tumors, Hematological Malignancies | Selectivity Assay (Need Mutant vs WT Proteins & GLUT3/4 cell lines) |
| Monoclonal Antibodies / ADCs | Academic institutions, Biotech startups | Triple-Negative Breast Cancer (TNBC), Colorectal Cancer | Internalization Assay & Flow Cytometry (Need stable cell lines via Lentivirus) |
| Gene Therapy / mRNA | Investigational programs | GLUT1 Deficiency Syndrome (G1D) | Functional Expression Validation (Need high-titer Lentiviruses) |